Ariane Morel

Marseille, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Cross-species cellular mapping and humanization of Fcγ receptors to advance antibody modeling.

Cross-species cellular mapping and humanization of Fcγ receptors to advance antibody modeling.

Journal: Science immunology
Published: January 30, 2026

Targeting BCMA in multiple myeloma with a trifunctional NK cell engager.

Targeting BCMA in multiple myeloma with a trifunctional NK cell engager.

Journal: Cell reports. Medicine
Published: August 20, 2025

A tetraspecific engager armed with a non-alpha IL-2 variant harnesses natural killer cells against B cell non-Hodgkin lymphoma.

A tetraspecific engager armed with a non-alpha IL-2 variant harnesses natural killer cells against B cell non-Hodgkin lymphoma.

Journal: Science immunology
Published: November 15, 2024

Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123.

Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123.

Journal: Nature biotechnology
Published: August 10, 2022

Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control.

Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control.

Journal: Open research Europe
Published: October 18, 2021

CD73-Mediated Immunosuppression Is Linked to a Specific Fibroblast Population That Paves the Way for New Therapy in Breast Cancer.

CD73-Mediated Immunosuppression Is Linked to a Specific Fibroblast Population That Paves the Way for New Therapy in Breast Cancer.

Journal: Cancers
Published: October 16, 2021

Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant.

Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant.

Journal: Cell reports. Medicine
Published: October 04, 2021

Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19.

Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19.

Journal: Cellular & molecular immunology
Published: June 15, 2020

Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis.

Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis.

Journal: Nature
Published: April 29, 2020

Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity.

Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity.

Journal: Cell
Published: December 05, 2018

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.

Journal: Cell
Published: June 13, 2018

A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies.

A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies.

Journal: Oncoimmunology
Published: January 13, 2015
Showing 1-12 of 12

Last Updated: 09/26/2026